Concurrent scientific working group session III |
OSZ 3 |
Hematopoietic stem cells (Chairs: Timm Schroeder/Claudia Waskow) |
09:00 - 09:15 |
Overview
Timm Schroeder, ETH Zürich BSSE, Basel, Switzerland |
09:15 - 09:30 |
T27 - CCND1/CDK4-mediated cell cycle progression provides a competitive advantage for human hematopoietic stem and progenitor cells in vivo
Nicole Mende, Dresden University of Technology |
09:30 - 09:45 |
T28 - The H3K4 histone methyltransferase Setd1b is required for haematopoietic stem cell homeostasis in mice
Kerstin Schmidt, Biotechnology Center TU Dresden |
09:45 - 10:00 |
T29 - Molecular and functional heterogeneity of dormant HSCs
Nina Cabezas-Wallscheid, German Cancer Research Center (DKFZ) Heidelberg |
10:00 - 10:15 |
T30 - High efficiency gene correction in hematopoietic cells by template-free CRISPR/Cas9 genome editing
Frank Schnütgen, University Hospital Frankfurt |
10:15 - 10:30 |
Working group discussion “Basic, translational and applied hematopoiesis” |
OSZ 4 |
Somatic stem cells (Chairs: Ana Martin-Villalba/Michael Rieger)
|
09:00 - 09:15 |
Overview
Ana Martin-Villalba, German Cancer Research Center (DKFZ) Heidelberg |
09:15 - 09:30 |
T31 - Visualization of the short-range Wnt gradient in the intestinal stem cell niche
Henner Farin, Georg-Speyer-Haus, Frankfurt |
09:30 - 09:45 |
T32 - Clonal heterogeneity within the exocrine pancreas
Damian Wollny, German Cancer Research Center (DKFZ) Heidelberg |
09:45 - 10:00 |
T33 - Single cell analysis of cellular mechanisms regulating adult neural stem cell fate
Onur Basak, Hubrecht Institute, Utrecht, Netherlands |
10:00 - 10:15 |
T34 - In vivo Ribotag analysis reveals translational control during neural stem cell differentiation
Avni Baser, German Cancer Research Center (DKFZ) Heidelberg |
10:15 - 10:30 |
Working group discussion “Somatic stem cells and development” |
OSZ 5
|
Stem cells in reg. therapies II: Mesenchymal stem/stroma cells (Chairs: Dirk Strunk/Karen Bieback)
|
09:00 - 09:15 |
Overview
Dirk Strunk, Paracelsus Medical University, Salzburg, Austria |
09:15 - 09:30 |
T35 - The transcription factor GATA2 controls mesenchymal stem cell fate
Alexander Tolkachov, Center for Cardiovascular Research, Charité, Berlin |
09:30 - 09:45 |
T36 - Attenuation of alloimmunity to human endothelial colony forming cells (ECFC) by interaction with mesenchymal stem/progenitor cells (MSPC)
Naima Souidi, Berlin-Brandenburg Center for Regenerative Medicine and Institute of Medical Immunology, Charité, Berlin |
09:45 - 10:00 |
T37 - Murine bone marrow derived mesenchymal stem cells as a putative therapy approach for influenza-virus induced pneumonia
Lina Jankauskaite, Universities of Giessen and Marburg Lung Center (UGMLC), Giessen |
10:00 - 10:15 |
T38 - Regenerative potential of human pluripotent stem cell-derived MSCs in a Gunn rat liver injury model
Lucas-Sebastian Spitzhorn, University Hospital of Düsseldorf |
|
Working group discussion “Stem cells in regenerative therapies” - future progress with MSCs |
OSZ 6 |
Programing and reprograming (Chairs: Micha Drukker/Frank Edenhofer) |
09:00 - 09:15 |
Overview
Micha Drukker, Helmholtz Center Munich |
09:15 - 09:30 |
T39 - An inducible overexpression system for rapid and highly efficient induction of mature cell types from human pluripotent stem cells
Matthias Pawlowski, Cambridge Stem Cell Institute, U.K. |
09:30 - 09:45 |
T40 - Reprogramming triggers endogenous LINE-1, Alu and SVA retrotransposition in human induced pluripotent stem cells affecting host gene expression
Gerald Schumann, Paul Ehrlich Institute, Langen
|
09:45 - 10:00 |
T41 – Efficient patterning of human pluripotent stem cells towards distinct mesendodermal subtypes simply by modulation of the bulk cell density
Henning Kempf, Hannover Medical School |
10:00 - 10:15 |
T42 - Direct in vivo glia-to-neuron conversion in the postnatal mouse cerebral cortex
Sophie Péron, Institute of Physiological Chemistry, Johannes Gutenberg University Mainz |
10:15 - 10:30 |
Working group discussion “Pluripotency and reprograming” |
10:30 - 11:00
|
Coffee break/industry exhibition |
Concurrent strategic working group session
|
OSZ 3 |
Stem cell technologies (Chairs: Frank Emmrich/Andreas Bosio) |
11:00 - 11:30 |
S1 - Technologies in genetic engineering of stem cells
Ulrich Martin, Hannover Medical School |
11:30 - 12:00 |
S2 - Genetic engineering of human pluripotent stem cells using TALENs nucleases
Sebastian Diecke, Max Delbrück Center, Berlin |
12:00 - 12:30 |
S3 - Mammalian genome engineering in the era of CRISPR/Cas
Ralf Kühn, Max Delbrück Center, Berlin |
OSZ 4 |
Career development (Chairs: Insa Schröder/Hartmut Geiger) |
11:00 - 11:15 |
Introduction
Insa Schröder, GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt |
11:15 - 12:00 |
S4 - How to apply in research and industry
Hanna Proner, academics/Die Zeit, Hamburg |
12:00 - 12:30 |
Panel discussion |
OSZ 5
|
Clinical trials and regulatory affairs (Chairs: Andreas Kurtz/Halvard Bönig) |
11:00 - 11:05 |
Introduction
Andreas Kurtz, Berlin-Brandenburg Center for Regenerative Medicine, Charité, Berlin
|
11:05 - 11:25 |
S5 - Regulatory aspects and classifications of stem cell based medicinal products
Egbert Flory, Paul Ehrlich Institute, Langen |
11:25 - 11:45 |
S6 - Accelerating the clinical development of cell based therapies
Natalie Mount, Cell Therapy Catapult, London, U.K. |
11:45 - 12:00 |
S7 - The ADIPOA-1/-2 trial - Adipose tissue derived stromal cells for osteoarthritis therapy
Oliver Pullig, Fraunhofer IGB, Würzburg branch |
12:00 - 12:15 |
S8 - Cell Therapy for bone defects: in vitro, in vivo, and first clinical results
Ingo Marzi, Goethe University Hospital, Frankfurt |
12:15 - 12:30 |
Panel discussion |
12:30 – 14:00
|
Lunch buffet/industry exhibition/poster viewing
|
12:45 - 13:45 |
Meet-the-expert table: Stem cell technologies – CRISPR/Cas Technology (Ralf Kühn) and – TALENs Technology (Sebastian Diecke) limited to 10 registered participants each |
12:45 - 13:45 |
Drop-in booth on regulatory affairs and clinical trials with Egbert Flory, Natalie Mount, u.a. |
OSZ 1 |
Joined session with LOEWE Center for Cell and Gene Theraty Frankfurt (CGT) |
14:00 - 14:45
|
Keynote lecture III
K3 - Pluripotency in the artificial cell space
Andras Nagy, Lunenfeld-Tanenbaum Research Institute, Toronto, Canada (Chair: Harald von Melchner)
|
14:45 - 15:30
|
Keynote lecture IV
K4 - Modeling and treating neural disease using human pluripotent stem cells
Lorenz Studer, Memorial Sloan Kettering Cancer Center, New York (Chair: Lenhard Rudolph) |
15:30 - 16:00
|
Coffee break/industry exhibition |
OSZ 1 |
CGT Session (Chair: Lenhard Rudolph) |
16:00 - 16:20 |
CGT1 - Regulation of second heart field progenitor cells: discovering key molecular players
Gergana Dobreva, Max Planck Institute for Heart and Lung Research, Bad Nauheim |
16:20 - 16:40 |
CGT2 - Functional systems analysis of the adult muscle stem cell identifies crucial regulators of muscle regeneration
Johnny Kim, Max Planck Institute for Heart and Lung Research, Bad Nauheim
|
16:40 - 17:00 |
CGT3 - Hematopoietic stem cell fate decision control at single cell resolution
Michael Rieger, Goethe University Hospital and LOEWE Center Frankfurt |
17:00 - 17:20 |
CGT4 - The Sleeping Beauty transposon system for genetic engineering in stem cells
Zoltán Ivics, Paul Ehrlich Institute, Langen |
OSZ 1 |
Closing ceremony |
17:30 - 17:45 |
Poster award ceremony and announcement of industry quiz winners
(Daniel Besser; GSCN)
supported by PeproTech GmbH |
17:45 - 18:00 |
Outlook and closing remarks
Incoming president: Ulrich Martin
|
End of GSCN conference 2015
|
|
Announcement: |
19:00 – 20:00 |
GSCN Public outreach event at the Hall West, Campus Westend
|
20:00 – 21:00 |
Reception public outreach event |